Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia.

about

Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia.

Item

http://www.wikidata.org/entity/Q42106569

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Combination of JAK2 and HSP90 ...... chronic myelogenous leukemia.

@en

Combination of JAK2 and HSP90 ...... chronic myelogenous leukemia.

@nl

type

Item

label

Combination of JAK2 and HSP90 ...... chronic myelogenous leukemia.

@en

Combination of JAK2 and HSP90 ...... chronic myelogenous leukemia.

@nl

prefLabel

Combination of JAK2 and HSP90 ...... chronic myelogenous leukemia.

@en

Combination of JAK2 and HSP90 ...... chronic myelogenous leukemia.

@nl

P1476

Combination of JAK2 and HSP90 ...... chronic myelogenous leukemia.

@en

P2093

Bastianella Perazzona

http://www.w3.org/2001/XMLSchema#string

Ralph B Arlinghaus

http://www.w3.org/2001/XMLSchema#string

Sandip N Chakraborty

http://www.w3.org/2001/XMLSchema#string

Xiaohong Leng

http://www.w3.org/2001/XMLSchema#string

Xiaoping Sun

http://www.w3.org/2001/XMLSchema#string

Yu-Hsi Lin

http://www.w3.org/2001/XMLSchema#string

P2860

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

The activity of hsp90 alpha promoter is regulated by NF-kappa B transcription factors

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

Mechanisms of transformation by the BCR/ABL oncogene.

c-Abl activates janus kinase 2 in normal hematopoietic cells.

Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)

STAT3 interacts directly with Hsp90.

P304

201-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/GENESANDCANCER.111

http://www.w3.org/2001/XMLSchema#string

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27551334

http://www.w3.org/2001/XMLSchema#string

P932

4979592

http://www.w3.org/2001/XMLSchema#string